Nexplanon (Etonogestrel)

Etonogestrel, the hormone released from Nexplanon, binds to progesterone receptors, suppressing the luteinizing hormone surge and preventing ovulation. It also thickens cervical mucus and alters the uterine lining, creating multiple barriers to fertilization and implantation.

The Nexplanon implant contains 68 mg of etonogestrel and is designed to release a low, steady dose over up to three years. The exact dosing schedule and timing of insertion are determined by the prescribing healthcare professional.

Nexplanon must not be used by women who are already pregnant, and it is contraindicated during pregnancy. While limited data exist for breastfeeding, the implant is generally considered compatible, but clinicians should evaluate individual risk‑benefit factors.

To request Nexplanon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with oral contraceptive pills, Nexplanon offers a once‑in‑a‑lifetime insertion lasting up to three years, eliminating daily compliance issues. Unlike intrauterine devices, it does not require uterine placement and can be removed easily if fertility is desired.

Nexplanon should be stored at room temperature, preferably below 25 °C, in its original sealed packaging. Protect the implant from moisture, direct sunlight and extreme temperatures to maintain hormone stability until insertion.

A qualified healthcare professional inserts Nexplanon subdermally in the inner side of the upper arm using a sterile applicator. The procedure is performed in an outpatient setting, and the implant remains in place for up to three years before removal or replacement.

Serious risks include deep vein thrombosis or pulmonary embolism, severe allergic reactions, infection or abscess at the insertion site, and rare cases of implant migration. Patients should seek immediate medical attention if they experience unexplained leg swelling, chest pain, severe rash, or signs of infection.

Nexplanon is contraindicated in women with a known or suspected pregnancy, active thromboembolic disease, estrogen‑dependent tumors, severe liver disease, or unexplained vaginal bleeding of unknown cause. A thorough medical history and clinical assessment are required before insertion.